Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 28, 2026, 7:41 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 289–312 of 754 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Estrogens Clear all
Recruiting Not applicable Interventional Accepts healthy volunteers

VEDA Study (DHEA vs Estradiol)

NCT07574216
View directory record Official record
Conditions
Post-menopause, Pre-menopause, Sexual Function, Menopause, Vaginal Dryness, Painful Intercourse
Interventions
DHEA ovals, Estradiol 0.01% Vag Cream
Drug
Lead sponsor
University of Arizona
Other
Eligibility
40 Years to 90 Years · Female only
Enrollment
324 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2031
U.S. locations
1
States / cities
Phoenix, Arizona
Source: ClinicalTrials.gov public record
Updated Sep 21, 2026 · Synced Oct 28, 2026, 7:41 PM EDT
Completed Phase 1 Interventional

Drug-Drug Interaction Study of Entinostat and Exemestane in Postmenopausal Women With ER+ Breast Cancer

NCT02820961
View directory record Official record
Conditions
Breast Cancer, Estrogen Receptor Positive Breast Cancer
Interventions
entinostat, exemestane
Drug
Lead sponsor
Syndax Pharmaceuticals
Industry
Eligibility
18 Years to 85 Years · Female only
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
3
States / cities
Denver, Colorado • Sarasota, Florida • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Dec 15, 2021 · Synced Oct 28, 2026, 7:41 PM EDT
Withdrawn Phase 4 Interventional

Oral Microdose Lupron Versus Luteal Estradiol Trial in Poor Responder In Vitro Fertilization (IVF) Patients

NCT00826839
View directory record Official record
Conditions
Infertility
Interventions
Oral contraceptive pill and microdose lupron, E2 patch/antagonist
Drug
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years to 50 Years · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 25, 2013 · Synced Oct 28, 2026, 7:41 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Effects of Sex Hormones on Circadian Rhythm in Men and Women

NCT00001285
View directory record Official record
Conditions
Bipolar Disorder, Circadian Rhythm, Depressive Disorder
Interventions
Not listed
Lead sponsor
National Institute of Mental Health (NIMH)
NIH
Eligibility
Female only
Enrollment
73 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
1991 – 2000
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 4, 2008 · Synced Oct 28, 2026, 7:41 PM EDT
Completed Not applicable Interventional

Diet and Estrogen Metabolism in Postmenopausal Women

NCT00003098
View directory record Official record
Conditions
Breast Cancer
Interventions
fat reduction with increased fiber, fat reduction without increased fiber
Other
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
50 Years to 69 Years · Female only
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2004
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Feb 1, 2016 · Synced Oct 28, 2026, 7:41 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Methylselenocysteine Effects on Circadian Rhythm

NCT01611038
View directory record Official record
Conditions
Breast Cancer, Prostate Cancer
Interventions
Methylselenocysteine, Placebo
Dietary Supplement
Lead sponsor
Rutgers, The State University of New Jersey
Other
Eligibility
21 Years to 60 Years
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2015
U.S. locations
1
States / cities
Piscataway, New Jersey
Source: ClinicalTrials.gov public record
Updated Sep 12, 2017 · Synced Oct 28, 2026, 7:41 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

The Safety and Effectiveness of Surgery With or Without Raloxifene for the Treatment of Pelvic Pain Caused by Endometriosis

NCT00001848
View directory record Official record
Conditions
Endometriosis, Pelvic Pain
Interventions
Raloxifene
Drug
Lead sponsor
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
NIH
Eligibility
Female only
Enrollment
612 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
1998 – 2006
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 22, 2016 · Synced Oct 28, 2026, 7:41 PM EDT
Completed Phase 2 Interventional Results available

Study of Efficacy of Ribociclib After Progression on CDK4/6 Inhibition in Patients With HR+ HER2- Advanced Breast Cancer

NCT02632045
View directory record Official record
Conditions
Metastatic Breast Cancer, Breast Carcinoma
Interventions
LEE-011, Fulvestrant, Placebo
Drug
Lead sponsor
Melissa K Accordino
Other
Eligibility
18 Years and older
Enrollment
169 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
13
States / cities
Birmingham, Alabama • Atlanta, Georgia • Chicago, Illinois + 7 more
Source: ClinicalTrials.gov public record
Updated Dec 6, 2024 · Synced Oct 28, 2026, 7:41 PM EDT
Terminated Phase 2 Interventional Results available

Radiation Therapy in Treating Post-Menopausal Women With Early Stage Breast Cancer Undergoing Surgery

NCT01754519
View directory record Official record
Conditions
Ductal Breast Carcinoma In Situ, Estrogen Receptor Negative, Estrogen Receptor Positive, HER2/Neu Negative, Invasive Cribriform Breast Carcinoma, Invasive Ductal Carcinoma, Not Otherwise Specified, Lobular Breast Carcinoma In Situ, Mucinous Breast Carcinoma, Papillary Breast Carcinoma, Progesterone Receptor Positive, Stage I Breast Cancer, Stage II Breast Cancer, Stage IIIA Breast Cancer, Stage IIIC Breast Cancer, Tubular Breast Carcinoma
Interventions
Therapeutic Conventional Surgery, Radiation Therapy, Laboratory Biomarker Analysis, Quality-of-Life Assessment
Procedure · Radiation · Other
Lead sponsor
Roswell Park Cancer Institute
Other
Eligibility
50 Years and older · Female only
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Jul 7, 2017 · Synced Oct 28, 2026, 7:41 PM EDT
Completed Phase 2 Interventional

Safety and Immunological Response Rate Study of THERATOPE® Vaccine in Metastatic Breast Cancer Patients

NCT00046371
View directory record Official record
Conditions
Breast Neoplasms
Interventions
THERATOPE® vaccine
Drug
Lead sponsor
Oncothyreon Canada Inc.
Industry
Eligibility
18 Years and older · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2005
U.S. locations
17
States / cities
Berkeley, California • San Francisco, California • Santa Monica, California + 14 more
Source: ClinicalTrials.gov public record
Updated Jan 23, 2008 · Synced Oct 28, 2026, 7:41 PM EDT
Suspended Phase 3 Interventional

Testing Low Dose Tamoxifen for Invasive Breast Cancer, LoTam Trial

NCT06671912
View directory record Official record
Conditions
Anatomic Stage 0 Breast Cancer AJCC v8, Anatomic Stage 1 Breast Cancer AJCC v8, Anatomic Stage IIA Breast Cancer AJCC v8, Estrogen Receptor-Positive Breast Carcinoma, HER2-Negative Breast Carcinoma, Breast Ductal Carcinoma In Situ, Breast Lobular Carcinoma In Situ
Interventions
Anastrozole, Letrozole, Exemestane, Tamoxifen, Mammogram, Magnetic Resonance Imaging, Dual X-ray Absorptiometry, Biospecimen Collection, Questionnaire Administration
Drug · Procedure · Biological + 1 more
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older
Enrollment
1,556 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2031
U.S. locations
728
States / cities
Anchorage, Alaska • Gilbert, Arizona • Goodyear, Arizona + 559 more
Source: ClinicalTrials.gov public record
Updated Sep 2, 2026 · Synced Oct 28, 2026, 7:41 PM EDT
Terminated Phase 2 Interventional Results available

A Phase II Study Comparing The Efficacy Of Venetoclax + Fulvestrant Vs. Fulvestrant In Women With Estrogen Receptor-Positive, Her2-Negative Locally Advanced Or Metastatic Breast Cancer Who Experienced Disease Recurrence Or Progression During Or After CDK4/6 Inhibitor Therapy

NCT03584009
View directory record Official record
Conditions
Estrogen Receptor-positive (ER+)/Human Epidermal Growth Factor Receptor (HER2)-Negative Locally Advanced or Metastatic Breast Cancer
Interventions
Venetoclax, Fulvestrant
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older · Female only
Enrollment
103 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
21
States / cities
Phoenix, Arizona • Springdale, Arkansas • La Jolla, California + 18 more
Source: ClinicalTrials.gov public record
Updated Jun 28, 2022 · Synced Oct 28, 2026, 7:41 PM EDT
Active, not recruiting Phase 1 Interventional

Study of AC699 in Patients With Estrogen Receptor Positive/Human Epidermal Growth Factor Receptor 2 Negative (ER+/HER2-) Locally Advanced or Metastatic Breast Cancer

NCT05654532
View directory record Official record
Conditions
Breast Cancer
Interventions
AC699
Drug
Lead sponsor
Accutar Biotechnology Inc
Industry
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
9
States / cities
Denver, Colorado • Orlando, Florida • Sarasota, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Sep 30, 2025 · Synced Oct 28, 2026, 7:41 PM EDT
Completed Phase 3 Interventional Results available

S1202: Duloxetine Hydrochloride for Muscle/Joint Pain in Early-Stage Breast Cancer Receiving Hormone Therapy

NCT01598298
View directory record Official record
Conditions
Breast Cancer, Musculoskeletal Complications, Pain
Interventions
duloxetine hydrochloride, placebo
Drug · Other
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
Up to 120 Years · Female only
Enrollment
299 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
714
States / cities
Anchorage, Alaska • Fairbanks, Alaska • Jonesboro, Arkansas + 475 more
Source: ClinicalTrials.gov public record
Updated Dec 16, 2022 · Synced Oct 28, 2026, 7:41 PM EDT
Recruiting No phase listed Observational

Active Surveillance in Older Women With ER+ Breast Cancer

NCT07262138
View directory record Official record
Conditions
Early Stage Estrogen Receptor (ER) Positive Breast Cancer
Interventions
Active Surveillance
Other
Lead sponsor
University of Pittsburgh
Other
Eligibility
70 Years and older · Female only
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 11, 2026 · Synced Oct 28, 2026, 7:41 PM EDT
Completed Phase 4 Interventional Results available

Preventing Recurrent UTI With Vaginal Estrogen

NCT05551949
View directory record Official record
Conditions
Recurrent Urinary Tract Infection, Urinary Tract Infections, Cystitis Recurrent
Interventions
Vaginal estradiol tablets
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
55 Years to 100 Years · Female only
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 5, 2026 · Synced Oct 28, 2026, 7:41 PM EDT
Completed Phase 3 Interventional

Study Evaluating Bazedoxifene/Conjugated Estrogen Combinations in Vasomotor Symptoms Associated With Menopause

NCT00238732
View directory record Official record
Conditions
Vaginal Atrophy
Interventions
Bazedoxifene/Conjugated Estrogen
Drug
Lead sponsor
Wyeth is now a wholly owned subsidiary of Pfizer
Industry
Eligibility
40 Years to 65 Years · Female only
Enrollment
650 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
63
States / cities
Birmingham, Alabama • Montgomery, Alabama • Scottsdale, Arizona + 60 more
Source: ClinicalTrials.gov public record
Updated Dec 28, 2007 · Synced Oct 28, 2026, 7:41 PM EDT
Completed Phase 2 Interventional Results available

Accelerated Partial Breast Radiation Therapy Using High-Dose Rate Brachytherapy in Treating Patients With Early Stage Breast Cancer After Surgery

NCT02526498
View directory record Official record
Conditions
Ductal Breast Carcinoma In Situ, Estrogen Receptor Positive, Invasive Breast Carcinoma, Progesterone Receptor Positive, Stage IA Breast Cancer, Stage IB Breast Cancer, Stage IIA Breast Cancer
Interventions
Accelerated Partial Breast Irradiation, High-Dose Rate Brachytherapy, Questionnaire Administration
Radiation · Other
Lead sponsor
Rutgers, The State University of New Jersey
Other
Eligibility
45 Years and older · Female only
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2021
U.S. locations
10
States / cities
Gilbert, Arizona • La Jolla, California • Royal Oak, Michigan + 6 more
Source: ClinicalTrials.gov public record
Updated May 15, 2023 · Synced Oct 28, 2026, 7:41 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

GDC-0941 and Cisplatin in Treating Patients With Androgen Receptor-Negative Triple Negative Metastatic Breast Cancer

NCT01918306
View directory record Official record
Conditions
Estrogen Receptor Negative Breast Cancer, Human Epidermal Growth Factor 2 Negative Carcinoma of Breast, Triple Negative Breast Cancer, Recurrent Breast Cancer, Stage IV Breast Cancer, Triple-negative Breast Cancer
Interventions
cisplatin, laboratory biomarker analysis, pharmacological study, dynamic contrast-enhanced MRI, diffusion-weighted MRI & chemical exchange saturation transfer MRI, GDC -0941
Drug · Other · Procedure
Lead sponsor
Vanderbilt-Ingram Cancer Center
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
16
States / cities
Birmingham, Alabama • San Francisco, California • Washington D.C., District of Columbia + 13 more
Source: ClinicalTrials.gov public record
Updated Jun 27, 2017 · Synced Oct 28, 2026, 7:41 PM EDT
Completed Phase 2 Interventional

Study of Tamoxifen in Well Differentiated Neuroendocrine Tumors and Hormone Receptor Positive Expression

NCT03870399
View directory record Official record
Conditions
Neuroendocrine Tumors, Progesterone Receptor Positive Tumor, Estrogen Receptor Positive Tumor
Interventions
Tamoxifen
Drug
Lead sponsor
AC Camargo Cancer Center
Other
Eligibility
18 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated May 6, 2024 · Synced Oct 28, 2026, 7:41 PM EDT
Terminated No phase listed Observational

Observational Study Analyzing RNA Expression Of Endometrial Biopsy Samples From Placebo, Bazedoxifene/Conjugated Estrogens And Raloxifene

NCT00847821
View directory record Official record
Conditions
Postmenopause
Interventions
Bazedoxifene 10 mg/CE 0.625 mg, Bazedoxifene 20 mg/CE 0.625 mg, Bazedoxifene 40 mg/CE 0.625 mg, Bazedoxifene 10 mg/CE 0.45 mg, Bazedoxifene 20 mg/CE 0.45 mg, Bazedoxifene 40 mg/CE 0.45 mg, Raloxifene 60 mg, Placebo
Drug
Lead sponsor
Wyeth is now a wholly owned subsidiary of Pfizer
Industry
Eligibility
40 Years to 75 Years · Female only
Enrollment
185 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
22
States / cities
Fort Myers, Florida • Gainesville, Florida • New Port Richey, Florida + 19 more
Source: ClinicalTrials.gov public record
Updated Sep 6, 2010 · Synced Oct 28, 2026, 7:41 PM EDT
Completed No phase listed Observational

Study of Urine Samples From Women With Newly Diagnosed Breast Cancer Enrolled on Clinical Trial UNMC-08105

NCT00959244
View directory record Official record
Conditions
Breast Cancer
Interventions
high performance liquid chromatography, laboratory biomarker analysis, mass spectrometry, medical chart review
Other
Lead sponsor
University of Nebraska
Other
Eligibility
19 Years and older · Female only
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Sep 1, 2023 · Synced Oct 28, 2026, 7:41 PM EDT
Recruiting Phase 3 Interventional

A Phase IIIb Study to Evaluate Camizestrant Plus Ribociclib in ER-positive, HER2-negative Advanced Breast Cancer

NCT07647328
View directory record Official record
Conditions
ER-Positive HER2-Negative Breast Cancer
Interventions
Camizestrant, Ribociclib
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
12
States / cities
Duarte, California • Palo Alto, California • Marietta, Georgia + 9 more
Source: ClinicalTrials.gov public record
Updated Oct 19, 2026 · Synced Oct 28, 2026, 7:41 PM EDT
Terminated Phase 2 Interventional

[18F]FES PET/CT in Endocrine Refractory Breast Cancer

NCT02409316
View directory record Official record
Conditions
Estrogen Receptor Positive Breast Cancer, Breast Neoplasm, Metastatic Breast Cancer
Interventions
[18F]FES
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older · Female only
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2025
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 11, 2026 · Synced Oct 28, 2026, 7:41 PM EDT